Compare
Editas Medicine, Inc. vs Voyager Therapeutics, Inc. vs Sangamo Therapeutics, Inc vs Kymera Therapeutics, Inc.
| Latest fiscal year | Editas Medicine, Inc. EDIT | Voyager Therapeutics, Inc. VYGR | Sangamo Therapeutics, Inc SGMOQ | Kymera Therapeutics, Inc. KYMR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $40.52M | $40.37M | $39.55M | $39.21M |
| Revenue growth (YoY) | +25.4% | -49.5% | -31.6% | -16.7% |
| Gross margin | n/a | n/a | n/a | 0.0% (computed) |
| Operating margin | -394.9% | -326.6% | -306.5% | -891.1% |
| Net margin | -395.0% | -296.5% | -310.8% | -794.0% |
| Net income | -$160.06M | -$119.72M | -$122.93M | -$311.35M |
| EPS (Diluted) | -$1.80 | -$2.04 | -$0.44 | -$3.69 |
| Operating cash flow | -$165.24M | -$132.47M | -$97.21M | -$232.89M |
| Free cash flow | -$165.85M | -$135.06M | -$97.31M | -$234.34M |
| Cash & equivalents | $146.65M | $65.30M | $20.95M | $357.01M |
| Total assets | $186.53M | $252.28M | $59.74M | $1.74B |
| Total liabilities | $159.25M | $56.20M | $74.01M | $163.15M |
| Shareholders' equity | $27.29M | $196.08M | -$14.27M | $1.58B |
| Return on year-end equity | -586.6% | -61.1% | n/a | -19.7% |
| Shares outstanding | 97.87M | 59.05M | 350.69M | 81.32M |
Revenue, most recent five fiscal years
| Fiscal year | Editas Medicine, Inc. | Voyager Therapeutics, Inc. | Sangamo Therapeutics, Inc | Kymera Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $40.52M Ended 2025-12-31 | $40.37M Ended 2025-12-31 | $39.55M Ended 2025-12-31 | $39.21M Ended 2025-12-31 |
| 1 year earlier | $32.31M Ended 2024-12-31 | $80.00M Ended 2024-12-31 | $57.80M Ended 2024-12-31 | $47.07M Ended 2024-12-31 |
| 2 years earlier | $78.12M Ended 2023-12-31 | $250.01M Ended 2023-12-31 | $176.23M Ended 2023-12-31 | $78.59M Ended 2023-12-31 |
| 3 years earlier | $19.71M Ended 2022-12-31 | $40.91M Ended 2022-12-31 | $111.30M Ended 2022-12-31 | $46.83M Ended 2022-12-31 |
| 4 years earlier | $25.54M Ended 2021-12-31 | $37.41M Ended 2021-12-31 | $110.70M Ended 2021-12-31 | $72.83M Ended 2021-12-31 |